BIOCAD continues legal battle with the exclusive distributor of Roche in Russia

21 February 2017

Russian drugmaker Biocad and R-farm, the exclusive distributor for Swiss pharma giant Roche (ROG: SIX), continue their legal battles in Russia regarding the sale of Roche’s blockbuster cancer drug Herceptin (trastuzumab) and a biosimilar produced by Biocad for the Russian market, according to an official spokesman of the Russian Ministry of Health.

The latest fight between the companies in Russia took place in the Khakassia Republic, (the Russian region in Siberia), where R- protested over the participation of the Biocad biosimilar in the state tender for the purchases of anti-cancer drugs.

Biocad’s trastuzumab biosimilar was approved in Russia in December 2015 under the trade name HERtiCAD.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK